We are delighted to announce our speakers line-up for the Innovation Forum 2016 conference. Follow us to keep up to date as we introduce our eminent speakers.
“As a CEO of a growing business you need to be able to refer to the expertise of others in order to make strategic decisions. Surrounding yourself with high quality people with the right expertise and experience puts you in the best position to do your own job well, and thus improve the results of the company as a whole.” – Linda Summerton
Linda Summerton, MA, PhD has over 25 years in the global pharmaceutical industry in large pharmaceutical companies, small biotechnology companies, private equity ventures and specialist service providers. Her main areas of therapeutic expertise are oncology and respiratory. Linda worked for 18 years at AstraZeneca, where she held a variety of roles, including project director for Iressa to first registrations in Oncology, Accolate to NDA in asthma, and culminating in being Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team (TAMT). She was also SVP Portfolio and Project Integration (PPI) at Merck KGaA, based in Darmstadt, leading the portfolio steering committees for Oncology, Cardiovascular and CNS development programmes as well as managing a department of commercial and development staff. Subsequently, Linda was Partner at Celtic Pharma Holdings Advisors LLP, where she took responsibility for identifying assets for investment, conducting due diligence on these assets and ensuring all investee companies had solid clinical development plans in place. She also managed assets once acquired, including roles as Head of Clinical and Preclinical Development at Cantab Biopharmaceuticals, Interim CEO at Novacta Biosystems Ltd. and CEO at Dialog Devices Ltd. Latterly Linda became a Senior Partner at TranScrip, a specialist service provider to the pharma and biotech industry, where she leads oncology services and directly supports clients working in oncology. Immodulon is her major commitment for the foreseeable future, it is a UK-based biopharmaceutical company pioneering immunotherapies to transform the way that cancer is treated in the world today. Linda has a first degree and PhD from Cambridge UK, and held a NATO post-doctoral Fellowship tenured at University of California, San Francisco.